OUR MISSION
The global psychedelics industry is expected to be worth over US$100 billion with the potential to save $1 trillion on lost productivity, disrupting the way we approach healthcare. As attitudes towards psychedelics shift dramatically, we are witnessing an international rise in clinical trials, academic research and commercial investment. The use of psychedelics as medicine is set to open up a new industry at pace. We help investors, operators and regulators navigate the many opportunities through data, intelligence and networking.
OFFERING
We demystify the legislative and regulatory environment surrounding a variety of psychedelics, helping our clients to navigate the changing landscape of each region.
We provide market forecasts and estimates for potential savings to society/economy which are likely to result from psychedelic therapies over the next decade.
We identify and analyse emerging trends for individual psychedelic therapies and monitor innovation and developments in this exciting, burgeoning industry.
PSYCH INVESTOR SUMMIT: RESEARCH & DEVELOPMENT
Join us on 7 July, 2021 for another global psychedelics industry event. Through our concise half-day programme, we will be showcasing the latest research and development in this exciting sector, alongside expanding businesses looking for capital – delivering the industry’s most promising opportunities directly to investors & funds.
Every PSYCH Investor Summit is an opportunity to engage with distinguished industry leaders, rising entrepreneurs and global psychedelics investors to share insights and help develop this emerging frontier.
Speakers:
Rick Doblin (MAPS)
Christian Angermayer (Aperion Investments)
Plus many more TBA
For Sponsorship & Media enquires contact our team.
DISRUPTING MODERN HEALTHCARE
Medical psychedelics are experiencing a renaissance, pushing forward the frontiers of healthcare innovation. The Psychedelics as Medicine Report: Second Edition provides unparalleled consumer insights and market intelligence from experts and industry leaders, helping to guide investors, operators and regulators through this transient phase. Download your free copy now.
The Psychedelics as Medicine Report: Second Edition examines:
- Proprietary consumer insights on attitudes, uses and behaviours
- Deep dives into the most transformative compounds and companies
- Key regulations, transformative trends and commercial opportunities
HIGHLIGHTS
PSYCH | Investor Summit: Europe & Asia – What Can Europe & Asia Learn From North America
PSYCH | Investor Summit: Europe & Asia – The Future of Psychedelic Medicine in Europe
PSYCH | Investor Summit: Europe & Asia – Psychedelic Patents & I.P.
PSYCH: Lessons Learned from 50 Years of Psychedelic Activism
NEWS AND INSIGHTS
Learning from the North American Psychedelics Market: is Europe Following in its Footsteps or Forging its Own Path?
Alternative health is a rising trend across all corners of the world; the global psychedelics industry is currently expected to be worth over US$100 billion, with the potential to save US$1 trillion on lost productivity, disrupting the way we approach healthcare. But how this industry is developing on either side of the Atlantic differs inContinue reading
Historic Phase 3 MDMA Clinical Trial Shows Success in Chronic PTSD
This week, the Multidisciplinary Association for Psychedelic Studies (MAPS) released findings from a groundbreaking Phase 3 clinical trial that suggest MDMA-assisted therapy will be an effective treatment for severe, chronic post-traumatic stress disorder (PTSD). ‘In our first Phase 3 study, roughly one third of the people had PTSD for 20 years or more, and yetContinue reading
Looking Back on the First PSYCH Investor Summit: Europe & Asia
On 21 April 2021, hundreds of attendees from investment, science and healthcare areas attended the PSYCH Investor Summit: Europe & Asia. The concise half-day virtual conference delivered the industry’s most promising opportunities directly to investors and funds in a day of networking, panels and company presentations from some of the most exciting enterprises in theContinue reading
THE PSYCHEDELICS NEWSLETTER
Expert analysis and intelligence, straight to your inbox. Join industry insiders and subscribe for exclusive news, data and insights from across the psychedelics industry.
